Changes to the Summary (01/09/2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Treatment of Childhood Langerhans Cell Histiocytosis (LCH)
Added Gadner et al. as reference 32.
Revised text to state that the first study that used 2-CdA to treat refractory and recurrent skin LCH disease reported on three patients who received two to four courses of 2-CdA at 0.7 mg/kg intravenously over 2 hours/day for 5 days. Also added text to state that in a series of five adults (one untreated and four with refractory LCH treated with 2-CdA at the same dose noted above), three patients achieved a complete remission and two patients achieved a partial remission.
Back to Top
